Here are 1-3 brief analogies for PDS Biotechnology (PDSB):

• Think of them as a clinical-stage Moderna, but with a primary focus on using the immune system to fight cancer, alongside vaccine development.
• Like a smaller, emerging Bristol Myers Squibb (BMS) dedicated to developing innovative immune-based treatments for cancer and infectious diseases.

• PDS0101 (HPV16): A lead clinical-stage cancer immunotherapy for recurrent/metastatic head and neck cancer, HPV-associated malignancies, and cervical cancer.
• PDS0102 (TARP): A preclinical cancer immunotherapy candidate targeting prostate and breast cancers.
• PDS0103 (MUC-1): A preclinical cancer immunotherapy candidate for ovarian, colorectal, lung, and breast cancers.
• PDS0104 (Tyrosinase-related protein 2): A preclinical candidate for the treatment of melanoma.
• PDS0201: A preclinical candidate for treating tuberculosis.
• PDS0202: A preclinical influenza vaccine candidate.
• PDS0203: A preclinical vaccine candidate for the prevention of COVID-19.

PDS Biotechnology (PDSB) is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines. As such, its product candidates are currently in various stages of clinical trials or preclinical development and are not yet commercially available.

Therefore, PDS Biotechnology does not currently have major customers that purchase its products, as its therapies have not received regulatory approval for commercial sale to individuals (patients) or other companies (e.g., hospitals, pharmacies, or distributors).

The company does engage in strategic "license and collaboration agreements" with entities such as the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. These relationships are critical for funding, research, development, and potential future commercialization, but these entities are partners and licensees rather than direct customers of commercial products.

• Lonza Group AG (LONN)

Frank Bedu-Addo, President and Chief Executive Officer

Frank Bedu-Addo is a co-founder of PDS Biotechnology, established in 2005, and has served as its President and CEO since its inception. He is recognized as a life science entrepreneur and executive with a track record of successfully starting and growing biotechnology organizations. Prior to PDS Biotechnology, Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc., where he managed all business and drug development operations. He also successfully established and managed Cardinal Health's East Coast biotechnology drug development operations. His earlier career included contributing to drug development in various roles at Akzo-Nobel, Elan (The Liposome Co.), and Schering-Plough. He holds an M.S. in Chemical Engineering and a Ph.D. in Pharmaceutics from the University of Pittsburgh.

Lars Boesgaard, Chief Financial Officer

Lars Boesgaard serves as the Chief Financial Officer for PDS Biotechnology. His background information regarding founding or managing other companies, selling companies, or a pattern of private equity backing is not readily available in the provided search results.

Gregory Conn, Chief Scientific Officer

Gregory Conn is the Chief Scientific Officer at PDS Biotechnology. His specific background details were not found in the provided search results.

Kirk Shepard, Chief Medical Officer

Kirk Shepard serves as the Chief Medical Officer at PDS Biotechnology. He oversees all clinical development programs for the company's Versamune® platform. Dr. Shepard is a recognized authority in clinical oncology and immunotherapy, having led the clinical development of multiple oncology drugs and immunotherapies over two decades. Previously, he was the global lead for several cancer trials at AstraZeneca and served as Chief Medical Officer at Callisto Pharmaceuticals and Cornerstone Pharmaceuticals. He was also a Medical Officer at the FDA's CBER Division, Oncology Branch, where he was involved in the medical review of Avastin® and Erbitux®. Dr. Shepard holds an M.D. from Duke University and completed his fellowship training in hematology and oncology at Tufts-New England Medical Center and the Dana-Farber Cancer Center.

Stephan Toutain, Chief Operating Officer

Stephan Toutain is the Chief Operating Officer at PDS Biotechnology. His specific background details were not found in the provided search results.

• Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, PDS Biotechnology's future success is critically dependent on the successful completion of clinical trials for its product candidates, particularly PDS0101, which is in Phase II. Failure to demonstrate safety and efficacy in clinical trials, or significant delays in these trials, could prevent the company from obtaining necessary regulatory approvals and subsequently commercializing its products.
• Funding and Capital Requirements Risk: The development of biopharmaceutical products through clinical trials is an expensive and lengthy process. PDS Biotechnology will require substantial additional funding to continue its research, development, and clinical activities. There is a significant risk that the company may not be able to raise sufficient capital on favorable terms, or at all, which could severely impact its ability to advance its pipeline or continue operations.
• Intellectual Property Protection and Competition Risk: PDS Biotechnology's competitive position relies on its ability to obtain, maintain, and protect its intellectual property rights for its product candidates. The biopharmaceutical industry is highly competitive, and the company's products, even if successful, may face intense competition from existing therapies or new treatments developed by larger, more established pharmaceutical companies. Challenges to its patents or the inability to secure robust intellectual property protection could significantly harm its business prospects.

PDS Biotechnology (PDSB) develops multifunctional cancer immunotherapies and vaccines. The addressable markets for its main products and services are as follows:

• PDS0101 (HPV16) for Human Papillomavirus (HPV) associated malignancies (including cervical, oropharyngeal, and anal cancers) and recurrent/metastatic head and neck cancer: The company has stated that there are multi-billion-dollar estimated U.S. market opportunities across HPV16-positive indications, prostate, and colorectal cancer indications. Over 630,000 cases of HPV-associated malignancies, including cervical, oropharyngeal, and anal cancer, occur worldwide annually.
  • For cervical cancer, the global treatment market size was valued at USD 6.9 billion in 2022 and is projected to reach USD 11.5 billion by 2032.
  • For head and neck cancer, the global market size was estimated at USD 2.3 billion in 2022 and is expected to reach USD 4.9 billion by 2032.
• PDS0102 (TARP) for prostate and breast cancers:
  • The global prostate cancer therapeutics market size was estimated at USD 17.0 billion in 2024 and is projected to reach USD 31.99 billion by 2030. In the 7MM (United States, EU4, United Kingdom, and Japan), the prostate cancer treatment market size was nearly USD 12,300 million in 2023.
  • The global breast cancer drugs market size was estimated at USD 36.62 billion in 2024 and is projected to reach USD 69.72 billion by 2033. The U.S. breast cancer market is projected to reach over USD 11.55 billion by 2034, increasing from USD 7.71 billion in 2025.
• PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers:
  • The global ovarian cancer market size was estimated to be USD 3.5 billion in 2023, with a projected compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. The U.S. ovarian cancer drugs market size is evaluated at USD 1.30 billion in 2025 and is projected to be worth around USD 2.57 billion by 2035.
  • The global colorectal cancer therapeutics market size was estimated at USD 12.79 billion in 2024 and is projected to reach USD 19.95 billion by 2034. In 2023, the United States held the largest Colorectal Cancer Market Share among the 7MM, accounting for approximately 40% of the total market.
  • The global lung cancer market size was estimated at USD 35.1 billion in 2024 and is expected to grow to USD 95.1 billion in 2034. The U.S. market for lung cancer was valued at USD 15.4 billion in 2024.
• PDS0104 for melanoma: The global melanoma therapeutics market size was estimated at USD 5.83 billion in 2024 and is estimated to reach USD 10.26 billion by 2030. The melanoma market in the top 7 markets (US, EU4, UK, and Japan) reached a value of USD 4.2 Billion in 2024 and is expected to reach USD 9.8 Billion by 2035.
• PDS0201 for tuberculosis: The global tuberculosis therapeutics market size was valued at USD 2.28 billion in 2024 and is expected to reach USD 3.40 billion by 2032. The U.S. tuberculosis therapeutics market size was valued at USD 0.12 billion in 2024 and is expected to reach USD 0.15 billion by 2032.
• PDS0202, an influenza vaccine candidate: The global influenza vaccine market size was estimated at USD 7.91 billion in 2023 and is projected to reach USD 12.58 billion by 2030. North America led the market with a 53.35% share in 2023.
• PDS0203, a vaccine for the prevention of COVID-19: The COVID-19 vaccine market size globally stood at USD 13.71 billion in 2025 and is projected to contract to USD 8.28 billion by 2030. The global COVID-19 Vaccine Market reached US$ 13.43 billion in 2024 and is expected to reach US$ 29.98 billion by 2033.

Expected Drivers of Future Revenue Growth for PDS Biotechnology (PDSB)

Over the next 2-3 years, PDS Biotechnology's revenue growth is expected to be driven primarily by the advancement of its clinical pipeline and associated strategic collaborations, rather than immediate product sales, as the company is currently in the clinical development stage with no reported product revenue. Key drivers include:

1. Potential Accelerated Approval and Initial Commercialization or Partnership of PDS0101: PDS0101 (Versamune® HPV), the company's lead product candidate, is in a pivotal Phase 3 clinical trial (VERSATILE-003) for HPV16-positive recurrent/metastatic head and neck cancer. PDS Biotechnology is actively pursuing an accelerated approval pathway for PDS0101 by amending the trial protocol to include progression-free survival (PFS) as an interim primary endpoint, which could shorten the timeline to regulatory submission and potential accelerated approval. Positive final results from the preceding VERSATILE-002 Phase 2 trial, which demonstrated a median overall survival of 39.3 months compared to a benchmark of 12-18 months, support this expedited path. If accelerated approval is achieved within the next 2-3 years, it could lead to initial revenue generation through early market access or significant upfront and milestone payments from a commercialization partner.
2. Achievement of Milestone Payments from PDS0101 Collaborations: As PDS0101 progresses through its Phase 3 clinical development and towards potential regulatory approval, the company may receive milestone payments from existing or new collaboration partners. The strong clinical data observed in earlier trials and the potential for accelerated approval make PDS0101 an attractive asset for partnerships, which typically include payments tied to development, regulatory, and commercial milestones.
3. Advancement and Potential Partnering of PDS01ADC: The company's second lead candidate, PDS01ADC, an IL-12 tumor-targeted immunocytokine, is currently being evaluated in multiple Phase 2 trials across various cancer indications under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Positive clinical data from these ongoing trials, particularly in metastatic castration-resistant prostate cancer, could attract new partnerships or expanded agreements, leading to additional milestone payments or licensing revenues within the specified timeframe.

Share Repurchases

• PDS Biotechnology's Board of Directors approved a share repurchase program of up to $20 million on May 23, 2022, which has been extended annually through May 2025.
• As of June 30, 2025, approximately $10.5 million had been utilized to repurchase 466,374 shares under this program.
• During the first six months of 2025, the company repurchased 40,925 common shares for an aggregate consideration of approximately $1.3 million.

Share Issuance

• PDS Biotechnology filed for a $150 million mixed shelf offering in August 2024, providing authorization for future equity issuances. [cite: Background]
• In February 2025, the company completed a registered direct offering that generated net proceeds of approximately $10.05 million. This offering involved the sale of shares and warrants, with an expected $11 million in immediate funding and a potential additional $11 million from warrant exercises. [cite: 8 from previous search]
• Cash flow statements show net common stock issuances of $22.6 million in 2024, $16.1 million in 2023, $9.9 million in 2022, and $48.5 million in 2021.

Inbound Investments

• In early 2025, PDS Biotechnology entered into a securities purchase agreement that raised $20.0 million, including $22.22 million in principal debentures, primarily used to retire prior debt.
• The February 2025 registered direct offering involved participation from new and existing healthcare-focused institutional investors. [cite: 8 from previous search]
• A November 2025 offering included the sale of shares and pre-funded warrants.

Outbound Investments

• PDS Biotechnology has not made any significant investments in or acquisitions of other companies within the last 3-5 years. [cite: 2 from previous search]

Capital Expenditures

• PDS Biotechnology reported investing cash flow of -$29,000 in 2024.
• Investing cash flow for 2023, 2022, and 2021 was negligible (reported as blank or 0K in the available data).